Uterine Hemorrhage (Uterine Bleeding)

Bleeding from blood vessels in the UTERUS, sometimes manifested as vaginal bleeding.
Also Known As:
Uterine Bleeding; Bleeding, Uterine; Uterine Bleedings; Uterine Hemorrhages; Hemorrhage, Uterine
Networked: 1190 relevant articles (67 outcomes, 118 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Anemia
2. Leiomyoma (Uterine Fibroids)
3. Myoma
4. Hemorrhage
5. Inflammatory Bowel Diseases (Inflammatory Bowel Disease)


1. Schatz, Frederick: 9 articles (03/2015 - 09/2002)
2. Learman, Lee A: 9 articles (07/2013 - 07/2003)
3. Lockwood, Charles J: 8 articles (03/2015 - 09/2002)
4. Washington, A Eugene: 8 articles (07/2013 - 07/2003)
5. Kuppermann, Miriam: 7 articles (07/2013 - 02/2004)
6. Krikun, Graciela: 7 articles (03/2011 - 09/2002)
7. Taneepanichskul, Surasak: 7 articles (04/2009 - 02/2003)
8. Vittinghoff, Eric: 7 articles (02/2006 - 09/2003)
9. Summitt, Robert L: 7 articles (02/2006 - 07/2003)
10. Varner, R Edward: 7 articles (02/2006 - 07/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Uterine Hemorrhage:
1. Levonorgestrel (Plan B)FDA LinkGeneric
2. Gonadotropin-Releasing Hormone (GnRH)FDA Link
3. Medroxyprogesterone Acetate (Depo-Provera)FDA LinkGeneric
4. IronIBA
5. Tranexamic Acid (AMCA)FDA Link
6. Progestins (Progestagens)IBA
7. Estradiol (Estrace)FDA LinkGeneric
8. N,N-dimethyl-4-anisidine (DMPA)IBA
9. Leuprolide (Lupron)FDA LinkGeneric
10. ferric carboxymaltoseIBA
12/01/2009 - "Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial."
01/01/2010 - "Ferric carboxymaltose (FCM, Ferinject) was effective and well tolerated in the treatment of iron-deficiency anemia (IDA) in nine, Phase III, randomized, controlled, multicenter trials in a diverse range of indications, including patients with inflammatory bowel disease (IBD), post-partum anemia (PPA) or abnormal uterine bleeding (AUB), chronic heart failure (CHF), non-dialysis-dependent chronic kidney disease (CKD) and those undergoing hemodialysis (HD). "
12/01/2009 - "The objective was to evaluate efficacy and safety of rapid, large-dose intravenous (IV) administration of ferric carboxymaltose compared to oral iron in correcting iron deficiency anemia due to heavy uterine bleeding. "
12/01/2009 - "In patients with iron deficiency anemia due to heavy uterine bleeding, rapid IV administration of large doses of a new iron agent, ferric carboxymaltose, is more effective than oral iron therapy in correcting anemia, replenishing iron stores, and improving quality of life."
01/01/2009 - "Intravenously administered ferric carboxymaltose was effective in the treatment of iron-deficiency anaemia in several 6- to 12-week, randomized, open-label, controlled, multicentre trials in various patient populations, including those with inflammatory bowel disease, heavy uterine bleeding or postpartum iron-deficiency anaemia, and those with chronic kidney disease not undergoing or undergoing haemodialysis. "

Therapies and Procedures

1. Hysterectomy
2. Endometrial Ablation Techniques
3. Curettage
4. Contraception (Birth Control)
5. Hormone Replacement Therapy (Therapy, Hormone Replacement)